Diversified Trust Co Acquires 5,170 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Diversified Trust Co lifted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 177.3% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 8,086 shares of the medical research company's stock after acquiring an additional 5,170 shares during the quarter. Diversified Trust Co's holdings in Bio-Rad Laboratories were worth $1,969,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. GeoWealth Management LLC grew its holdings in shares of Bio-Rad Laboratories by 342.9% in the fourth quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock worth $31,000 after purchasing an additional 72 shares during the last quarter. Picton Mahoney Asset Management lifted its holdings in Bio-Rad Laboratories by 55.6% in the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after buying an additional 35 shares during the period. Curat Global LLC bought a new stake in shares of Bio-Rad Laboratories in the 1st quarter worth approximately $34,000. Cape Investment Advisory Inc. purchased a new position in shares of Bio-Rad Laboratories during the fourth quarter valued at approximately $38,000. Finally, Brown Brothers Harriman & Co. raised its holdings in shares of Bio-Rad Laboratories by 2,928.6% during the fourth quarter. Brown Brothers Harriman & Co. now owns 212 shares of the medical research company's stock valued at $70,000 after acquiring an additional 205 shares in the last quarter. Hedge funds and other institutional investors own 65.24% of the company's stock.

Bio-Rad Laboratories Stock Up 2.5%

Shares of NYSE:BIO traded up $6.12 on Tuesday, hitting $247.44. 179,645 shares of the company traded hands, compared to its average volume of 341,957. The company has a market cap of $6.73 billion, a PE ratio of -3.25 and a beta of 0.93. The stock has a 50 day simple moving average of $235.54 and a 200-day simple moving average of $273.67. Bio-Rad Laboratories, Inc. has a 52 week low of $211.43 and a 52 week high of $387.99. The company has a quick ratio of 4.43, a current ratio of 5.99 and a debt-to-equity ratio of 0.18.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical research company reported $2.54 EPS for the quarter, beating analysts' consensus estimates of $1.73 by $0.81. Bio-Rad Laboratories had a negative net margin of 85.16% and a positive return on equity of 4.32%. The firm had revenue of $585.40 million for the quarter, compared to analysts' expectations of $573.01 million. During the same quarter in the prior year, the company posted $2.30 earnings per share. The business's revenue for the quarter was down 4.2% on a year-over-year basis. As a group, research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Citigroup reduced their price objective on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Royal Bank Of Canada reduced their target price on Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Wall Street Zen cut Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Sunday, June 8th. UBS Group decreased their price objective on Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Finally, Wells Fargo & Company dropped their target price on shares of Bio-Rad Laboratories from $260.00 to $245.00 and set an "equal weight" rating on the stock in a report on Monday, June 9th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $324.25.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.